Overview

Pitolisant in Refractory Restless Legs Syndrome

Status:
Recruiting

Trial end date:
2023-05-01

Target enrollment:

Participant gender:

Summary

This is an open-label trial in Restless Legs Syndrome (RLS) patients inadequately treated with standard therapy, defined by an IRLS score greater than 15. Investigators hypothesize that the study drug, Pitolisant (Wakix), may improve RLS symptoms.

Phase:

Phase 4

Details

Lead Sponsor:

William Ondo, MD

Collaborator:

Harmony Biosciences, LLC